Vexplatin-50/Vexplatin-100 Patient Counseling Information

Information of patients: The product should not be diluted in sodium chloride solution or in chloride containing solution. Patients and patient's caregivers should be informed of the expected adverse effects of Oxaliplatin particularly its neurologic effects both the acute, reversible effects and the persistent neurosensory toxicity.
Patients should be informed that the acute neurosensory toxicity may be precipitated or exacerbated by exposure to cold or cold objects.
Patients should be instructed to avoid cold drinks, use of ice, and should cover exposed skin prior to exposure to cold temperature or cold objects.
Patients must be adequately informed of the risk of low blood cell counts and instructed to contact their physician immediately should fever, particularly if associated with persistent diarrhea, or evidence of infection develop.
Patients should be instructed to contact their physician if persistent vomiting, diarrhea, signs of dehydration, cough or breathing difficulties occur or signs of allergic reaction appear.
Oxaliplatin is incompatible in solution with alkaline medications or media (such as basic solutions of 5-fluorouracil) and must not be mixed with these or administered simultaneously through the same infusion line. The infusion line should be flushed with 5% glucose solution prior to administration of any concomitant medication.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration and discarded if present.
Needles or intravenous administration sets containing aluminum parts that many come in contact with Oxaliplatin should not be used for preparation or mixing of the drug. Aluminum has been reported to cause degradation of platinum compounds.
Have a known history of hypersensitivity to oxaliplatin, pregnancy, breast feeding.
Have myelosuppression prior to starting first course, as evidenced by baseline neutrophils <1.5 x 10⁹/L and or platelet count of <100 x 10⁶/L.
Have a peripheral sensitive neuropathy with functional impairment prior to first course.
Have a severely impaired renal function (creatinine clearance less than 30 mL/min).